Ashwood V A, Cassidy F, Coldwell M C, Evans J M, Hamilton T C, Howlett D R, Smith D M, Stemp G
SmithKline Beecham Pharmaceuticals, Medicinal Research Centre, Harlow, Essex, England.
J Med Chem. 1990 Sep;33(9):2667-72. doi: 10.1021/jm00171a051.
The synthesis and antihypertensive activity of a series of novel 4-(substituted-carbonylamino)-2H-1-benzopyran-3-ols, administered orally to conscious spontaneously hypertensive rats, are described. Optimum activity was observed for compounds with alkyl, amino, or aryl groups flanking the carbonyl group. Of the alkyl and amino series the most potent compounds contained the methyl and methylamino groups, respectively. Several analogues have been compared with cromakalim (1) for their effects on potassium ion efflux in the rabbit mesenteric artery using rubidium-86 as a marker. The ability of each compound to enhance rubidium-86 efflux is approximately parallelled by its blood pressure lowering activity, and thus these analogues, like compound (1), belong to the series of drugs which have been classified as potassium-channel activators.
本文描述了一系列新型4-(取代羰基氨基)-2H-1-苯并吡喃-3-醇的合成及其对清醒自发性高血压大鼠口服给药后的降压活性。观察到羰基两侧带有烷基、氨基或芳基的化合物具有最佳活性。在烷基和氨基系列中,最有效的化合物分别含有甲基和甲氨基。使用铷-86作为标记物,比较了几种类似物与克罗卡林(1)对兔肠系膜动脉钾离子外流的影响。每种化合物增强铷-86外流的能力与其降压活性大致平行,因此这些类似物与化合物(1)一样,属于已被归类为钾通道激活剂的药物系列。